๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX ยท Real-Time Price ยท USD
48.06
-0.24 (-0.50%)
Nov 20, 2026, 2:08 PM EST - Market open
โ† View all transcripts

UBS Global Biopharma Conference 2026

Nov 16, 2026

Summary

FILSPARI sales rose ~120% YoY in Q3, with early FSGS uptake supporting a goal of $3B net product sales by 2033. Pegtibatinase phase III data are expected in H2 2027, while civorebrutinib is advancing toward late-stage development.

Dejia Zhang
Investment Banking Coverage Team, UBS

Hello. All right. Thank you, everyone, for coming today. My name is Dejia Zhang, and I am on the UBS Investment Banking Coverage Team. I am so excited to have all of you here and attend our inaugural conference this year in London. I am also really excited to announce Chris Cline as the Chief Financial Officer of Travere Therapeutics.

Chris Cline
CFO, Travere Therapeutics

Well, thank you, Dejia, and thank you, UBS, for having us. It is great to be here with you all, and I am very excited to spend some time talking about Travere Therapeutics. I will be making forward-looking statements, so please see our 10-K and 10-Q for full risk factors and forward-looking disclosures. When we think about Travere Therapeutics, we are exclusively focused on delivering life-changing therapies for people living with rare disease. We do that in a host of different ways. The first is in the commercial side, where we have a full commercial organization that is delivering multiple approved medicines, FILSPARI for IgA nephropathy, as well as FSGS, two rare progressive kidney diseases, and Thiola EC and Thiola, which are our legacy businesses that are targeting cystinuria, basically the standard of care for another rare kidney disease.

We have seen very excellent execution and growth in the recent years in the commercial side of the business, but we also have a pipeline that has two programs that have best-in-class potential, one for a disease called classical homocystinuria, or HCU, and this is pegtibatinase, it is an enzyme replacement therapy that is currently in phase III. Also civorebrutinib, or sibo, and this is our most recent addition to the pipeline. This is a next-generation BTK inhibitor that we are going to be moving forward in multiple immune-mediated kidney diseases. In order to continue our trajectory of performance and growth in the recent history and to really turn that into durable long-term growth, we are focusing on four key strategic pillars. These pillars, the first two of which are focused on FILSPARI, and FILSPARI has had significant growth both in IgA and more recently in FSGS.

What we want to make sure we are doing is focusing our efforts on continuing that momentum and continuing to maintain that foundational placement that has been built. The first growth driver is in IgA nephropathy, and we have been approved here since February of 2023. FILSPARI is the only nephroprotective medicine that can replace the historical standard of care, and that is exactly what our commercial organization has been doing in reaching patients. The goal of the priority number one is to continue to maintain that momentum as we see the IgA nephropathy space continue to expand and the treatment paradigm evolve. The second growth driver is tied to the recent approval in FSGS for FILSPARI. In April of this past year, we got approved for focal segmental glomerulosclerosis, or FSGS, and here what we have seen is a very strong start to the commercial launch.

We're only two quarters in, but we're seeing broad adoption and very strong response from the nephrology community for having the first and only approved medicine for FSGS, and importantly, that's for both adults and pediatric patients. The second priority here really is focused on continuing that early adoption and getting to that foundational positioning in FSGS as well. The third and the fourth priorities are really tied towards the next wave of growth that we expect to have alongside and beyond FILSPARI. These are tied to the pipeline, and the third priority being focused on pegtibatinase. As I mentioned before, this is our enzyme replacement therapy that's targeting classical homocystinuria, and if approved, it would be the first and only disease-modifying therapy for classical HCU.

We're currently enrolling a phase III study called the HARMONY Study that we expect to be able to support a BLA submission. Our current focus there is to ensure that we get to full enrollment so that we can have a data readout in the second half of next year, and we're firmly on track to do that. The last priority that you see here is on civorebrutinib. This again, this is the latest addition to our pipeline. Here, the main goal is to begin development as what we look at as a potential pipeline and a product. For civorebrutinib, we've been licensed this from Everest Medicines, and so we're in the process of opening up an IND in the U.S.

Our goal here is to submit and have that cleared so that we can begin our dosing work to do bridging, as well as some optimization before we go and engage with FDA to establish our global regulatory plans for multiple late-stage studies and immune-mediated kidney diseases. So very exciting time and very clear focus on these key growth drivers that we expect to drive value both in the near term and then also as we move forward into the next decade. Let me start first with FILSPARI and really focus in on IgA nephropathy and FSGS. When you think about FILSPARI, we have an overall opportunity to reach more than 100,000 patients with these two diseases. IgA nephropathy is believed to have about 70,000 addressable patients, and FSGS is more than 30,000.

We expect that both of these diseases are going to see increased biopsy, increased diagnosis, and earlier treatment as physicians continue to adapt to new treatment guidelines, but then also as we see more and more treatments becoming available, greater education and awareness. So a very large and expanding market opportunity as a whole for FILSPARI. FILSPARI is very uniquely placed. It is a once-a-day oral medication. It is the only non-immunosuppressive medicine that has been trialed against the historical standard of care and can actively replace or upgrade what patients have historically used as their foundational care. So, very clear differentiated profile that will enable it to continue to be used. What we see is that with its profile of once daily oral and having a generally safe and well-tolerated profile, that patients are highly compliant and persistent on therapy when they begin.

If a patient starts therapy, they typically will stay on for extended periods of time. We have a very strong commercial platform to leverage. When you think about the call points for nephrology, we call on about 7,000 nephrologists, and there's a very high overlap between those that are seeing IgA nephropathy patients and FSGS patients, more than 80%. We've got a built-in expertise, established relationships, and years of experience to be able to continue meeting the needs of the physicians and reaching patients. When you think about that overall and put it together, we look at this as an opportunity of potentially more than $1 billion or $3 billion in net sales potential by the year 2033. We've talked historically about IgA nephropathy being larger than $1 billion potentially, and FSGS being even larger than that.

Everything that we see so far in our trajectory in both markets continues to support that. I'll talk a little bit about that now, where we look at our third quarter results. In the third quarter, we saw U.S. net product sales of FILSPARI increase about 120% over the same period last year to eclipsing $200 million. This was really driven by a host of different factors. First, for those patients that have already been prescribed FILSPARI, in IgAN especially, you see strong persistence and compliance, as I mentioned before. That's a growing base of revenue that we're seeing being contributed from IgA nephropathy.

We're also seeing in the second quarter of launch now for FSGS, this is the first time that we're seeing a contribution from the revenues in that indication, which has been encouraging to see how quickly we've been able to both see strong conversion, but then also from a payer access standpoint, all of the work that's gone to date with payers is translating into early adoption and reimbursement. On the demand side, we saw 1,932 new patient start forms, which is incredibly strong and especially encouraging given typically in the third quarter, we see summer seasonality. That's driven across the market by fewer physicians, or by fewer patients seeing their physicians and people taking vacation. This is something that we've seen in years past. There's typically a slight lowering in demand.

We were very encouraged to see the continued strong uptake of FILSPARI both in IgA and FSGS. We're seeing this happen, importantly, with both new and repeat prescribers. In IgA nephropathy, even though we're a number of years into the launch, we're still identifying new prescribers, and you're seeing continued deepening within practices. In FSGS, we're also seeing both new and repeat prescribers. Interestingly, with FSGS, what we commented on is that roughly 2/3 of physicians have only written a prescription to one patient within their practice. We know that in many of the practices, or most of the practices, they're going to have a handful or more patients. We know that they are just in the early days of adoption. Very encouraging from a demand perspective. I'll talk a little bit about each of the individual indications.

Starting first with IgA nephropathy, you are talking about a very progressive disease where high-risk patients typically will advance to kidney failure within around 11 years. Unfortunately, this is happening at the peak of life for these patients. You are talking about individuals who are in their mid-20s to late 30s, and oftentimes they will go to transplant or dialysis, and oftentimes transplant will fail due to recurrence. So a devastating disease hitting people at the prime of their life. There are more than 70,000 patients that we believe are out there, and we are still early in being able to reach the overall population. I will talk a minute about the current KDIGO guidelines. We saw a shift here in 2025 when the KDIGO guidelines were updated. It used to be believed that for IgA nephropathy, if a patient was around 1 g of proteinuria, they were largely stabilized.

But data over time has shown us that the treatment goal really should be 0.5 g or preferably complete remission, 0.3 g of proteinuria. The new KDIGO guidelines reflected that adjustment in terms of more ambitious treatment targets. They also included FILSPARI as being the foundational care, and also to potentially use it ahead of RAS inhibition. The KDIGO guidelines have also now suggested that you really should be looking to biopsy patients with any sign of proteinuria and aiming to treat earlier. So that is driving a nice shift within the nephrology space for nephrologists to really seek out their patients, seek treatment earlier, and to drive to the lowest proteinuria they possibly can get, because proteinuria is the only validated biomarker to help make those decisions on a regular basis. Also within the KDIGO guidelines is this evolving treatment paradigm, which shows two aspects of the disease.

For nephrologists, they think about having to treat both the overactivation in the kidney, and this is where FILSPARI plays a key role, as well as the overactivation in the immune system. There is no single medicine that addresses both of these aspects of the disease, and really what we are seeing happen is an upgrade, if you will, of historical standards of care on both different sides, and them being used in combination. Starting on the kidney side, what has historically been used as the standard of care has been RAS inhibition and SGLT2, and now we are seeing that FILSPARI is becoming foundation and being that first choice to switch from the RAS inhibition, and even use ahead of RAS inhibition, to address the overactivation specifically in the kidney, and the nephroprotective properties of FILSPARI really lend well to that adoption.

On the other side of the paradigm is the immune system, is targeting the overactivation of the immune system, and historically, this has been the role for steroids and complement inhibitors, and now we are seeing the evolution of the APRIL-BAFF B-cell approaches that have encouraging data and being used in that side of things. Really what we anticipate seeing going forward is that FILSPARI is going to maintain foundational positioning and be used in combination with other medicines on the targeted immune side of things, much like it has been in the past with FILSPARI prior to any of the newer treatments becoming available. FILSPARI was used with Tarpeyo or steroids or complement inhibitors. Now it is just evolving to have some of the newer treatments that have been approved recently taking the place of those on the immune side.

We're in the early stages here of a very exciting evolution of the treatment paradigm in IgA nephropathy, and FILSPARI, we expect to maintain its foundational positioning in an expanding market. I'll touch next on FSGS, and FSGS is an even more progressive rare kidney disease, and one where you have a kidney survival rate of around seven years, which is the shortest of all of the primary glomerular diseases. FSGS is responsible for tens of thousands of patients staring at kidney failure and evaluating dialysis or kidney transplant. Similar to IgA nephropathy, FSGS has a very high recurrence rate post-transplant, and so, unfortunately, a disease that, up until just recently with the approval of FILSPARI, has had very few treatment options and certainly nothing that has been particularly effective.

In FSGS, the number one diagnostic factor, or the number one factor that physicians use to understand disease severity and progression, is proteinuria. When we look at what data has been demonstrated for FILSPARI in our phase III DUET study, is a significant reduction in proteinuria. Really, this is the basis of what ultimately got FILSPARI approved this past April. What you see here on the chart on the left is that in the population without nephrotic syndrome, and this is the indication that we have for FSGS, for patients without nephrotic syndrome, you see a significant reduction in proteinuria relative to irbesartan. Irbesartan here is max tolerated dose or max dose, 300 mg, so it's an active comparator. You also see that in the chart to the right as well, where you have in the overall population a similar but slightly smaller magnitude.

These data, alongside the additional data that showed, and this correlated to patients achieving key thresholds of proteinuria reduction, whether that's 1.5, KDIGO 1.5 for complete remission, as well as clinically meaningful improvements on eGFR, are what ended up supporting the approval for FILSPARI in FSGS this past April. Really what we're looking at for FSGS in the market, if you break it down, there's multiple different subtypes of FSGS. You can see here that we have primary and genetic, as well as secondary and undetermined cause. As I mentioned before, our label is for FILSPARI or for FSGS patients without nephrotic syndrome. That's irrespective of these subtypes of disease.

We saw in our study that we had a consistent response across all different patients that were in the study, and we think that based off of the data that we have to date, that there's more than 30,000 addressable patients out there with FSGS that fall into these categories. We also expect this to grow over time, and we expect this to grow over time for a couple of different reasons. The first, going back to what our indication statement is, which is it's for patients without active nephrotic syndrome. We know that patients that have active nephrotic syndrome, which is having elevated proteinuria, low albumin, and edema, they can be brought out of that state. If a patient can be brought out of that state, then they can be eligible for FILSPARI.

But also, we expect to see additional diagnosis really done with increased biopsy and physicians now having a treatment for the first time there to drive awareness and have the discussion with patients to do the biopsy and seek treatment. One other element of this is specific to secondary FSGS, where here, historically, physicians have not sought, at least as frequently, to biopsy patients because it is secondary to hypertension, or other diabetes, et cetera. Now with the treatment available, we believe that you are going to see an increased rate in secondary biopsies as well, which can potentially expand this market meaningfully. Overall, with FILSPARI, we have got an excellent opportunity, and we are in the early stages of reaching the more than 100,000 addressable patients and well on track to achieve our goal of $3 billion in net product sales by 2033.

I will turn next to the pipeline, and starting with pegtibatinase, and this is, again, our enzyme replacement therapy for classical homocystinuria. Homocystinuria, or HCU, is driven by a defect in the CBS enzyme, and that defect or the lack of the activity of the CBS enzyme translates to a toxic accumulation of total homocysteine. The total homocysteine, us here in the room would normally be clearing it on a regular basis, but for these patients, it builds up over time, and it translates to clinical outcomes that can be very grave. So things like eye lens dislocation, cognitive impairment, or life-threatening thrombotic events. Oftentimes, you see it before the age of 16, or even half of patients by the age of 29 having either a heart attack or stroke.

There are believed to be about 7,000-10,000 patients in the U.S., similar numbers abroad, and there are no approved treatment options today that are actually addressing the underlying cause of the disease. The things that are available today, vitamin B6, betaine, and low-protein diets, are highly ineffective and/or difficult to live on a daily basis. When we think about the addressable market in the future or at launch, we talked to about 3,500 patients in the U.S., similar numbers abroad. That is largely driven by the fact that you have newborn screening today in the U.S. that is relatively poor for HCU.

We believe that with better newborn screening, and really this is about measuring total homocysteine rather than methionine and having consistent diagnostics state to state, we believe that you will see increased patient diagnosis early in life, and with an approved therapy and the ability to drive education awareness, that we are going to see more and more patients identified with HCU. Now, if we turn to the data, and this is what has us very excited about pegtibatinase's potential to be able to help this community, these are data from our phase I/II study. You can see here a very clear dose response as you go up from one mg to 2.5 mg per kg, and especially when you transition over to twice weekly. Most importantly, you see in that high-dose cohort, you see a 67% mean relative reduction from baseline.

A dramatic reduction, especially when you think about it relative to placebo, where there was no meaningful change in total homocysteine levels, as you would expect with an enzyme replacement therapy going against a placebo. Also very important is that all patients in the high-dose cohort got below the clinically meaningful threshold of 100 micromoles. The guidelines will tell you in HCU that if you can get patients below 100 micromoles, you are at a lower risk of having these clinical outcomes that I mentioned earlier. If you can get patients below 50, then you can consider adding additional protein to the diet. We saw in our higher dose cohorts, all patients get below 100. We saw a number of patients get below 50, and we even saw a patient get into normalization, which is the first time that has been seen in HCU.

We also saw on the other biomarkers that we look at, methionine and cystathionine activity, that suggests that you are reigniting the activity of the CBS enzyme, and pegtibatinase was generally well tolerated at all doses. Going forward, we are moving pegtibatinase, or pegtibatinase has already moved into a phase III study called the HARMONY Study. Here, we are aiming to replicate as much as we can from phase I/II, given the strong results, and we are looking at a similar primary endpoint. We are looking here at reduction in total homocysteine average from week six to week 12. We will be looking at pegtibatinase in a blinded period for up to 24 weeks, and that is really to give us some additional durability and safety data. There are two notable differences from our phase I/II. The first being we introduced here a diet standardization protocol.

The goal of that really is to make sure that patients can align with the nutritionist on the level of protein that they are going to have in their diet for the open-label period. Each individual patient will make their own plan and stay on that plan throughout the double-blind period so that it eliminates or at least mitigates any kind of variability around the total homocysteine measurements, because those can get affected by changes in diet. We believe that that is going to make the results potentially even stronger. The second part that we have added into this is the phase IIIb ENSEMBLE study, which is an open-label study that is going to evaluate, most importantly, whether or not patients who reach certain thresholds of total homocysteine, if they can introduce protein to their diet and still maintain that level of total homocysteine reduction.

We hear very regularly from the patient community that the day-to-day life, being on a highly restrictive protein diet that tastes terrible, that is highly difficult to get and expensive, not to mention the social consequences of not being able to have a normal meal with your friends or family, it is something that is an important daily consequence of the disease. We are looking at how we might be able to modify that with treatment with pegtibatinase, and we are looking forward to seeing the first data coming from that. Everything here is going very well from an enrollment perspective, and we are on track to have data in the second half of next year. Lastly in the pipeline is civorebrutinib, or sibo. As I mentioned before, this is our next-generation BTK inhibitor that we are very excited about.

We brought this product in for a number of different reasons. First was, we felt like there was a more targeted approach to B-cell activation or inhibiting B-cell activity than some of the other therapies that have been looked at for rare kidney disease. Specifically, we believe that there's value in being able to selectively address the B-cell pathway rather than doing full B-cell depletion, et cetera. Then also from a dosing perspective, being an oral medicine, we thought was very important for the rare kidney community. When you think about it relative to other BTK approaches, there's differentiation in both the selectivity profile, the potency, and the covalent reversible nature of civorebrutinib. So very good approach here that ties nicely into our already longstanding rare nephrology franchise, especially when you think about the complementary nature with FILSPARI.

Thus far, we have identified three areas that we are really focused on moving sibo forward in at the moment. These three are PMN and our primary membranous nephropathy. Here we think that there's about 90,000 prevalent patients out there. Then on immune-mediated and FSGS and MCD, that's another more than 40,000 patients, prevalent patients that we believe could benefit from a therapy like civorebrutinib. What we are looking to do is first move into PMN, FSGS, MCD, with PMN being the sort of lead target, if you will, or lead indication, if you will, because we have clear data here. First, a little bit on PMN, a very significant unmet need. You've got more than 70% of patients with very active nephrotic syndrome.

Even for those patients that aren't yet in nephrotic syndrome, the vast majority of them are going to progress there in one to two years. Really, with the long-term side of things, you're looking at patients, nearly half of them, facing kidney failure within 10 years. Outside of that, you have the normal day-to-day challenges of brain fog, fatigue, et cetera. To date, there's only one approved medicine, so there's a very clear opportunity for more treatment options and effective things for patients to choose from. What got us excited about civorebrutinib in PMN specifically are the data that we see here from the phase I/II study that show clear proof of concept. Here you can see that treatment with sibo resulted in approximately 90% reduction in anti-PLA2R, the key antibody within PMN.

You see that in a very rapid response that is sustained over an extended period of time. This is data out to 52 weeks. What we saw after looking at anti-PLA2R was a very clear correlation in proteinuria levels. These followed the anti-PLA2R decrease, and you saw, again, a sustained decline down to roughly 80% reduction by week 36 and then sustained there afterwards following treatment discontinuation. So very clear efficacy signal from both anti-PLA2R and on proteinuria. From a safety perspective, what we were most focused on in looking at this data from a diligence perspective was looking for any of the clinically meaningful AEs that you have typically seen in the earlier generation BTKs, of which we have not seen any, either neutropenia, hemorrhage, or arrhythmia. What we see here is a generally safe and tolerable profile.

The next steps with sibo, again, as I mentioned earlier, we're going to submit and get clearance for our IND. Then we'll move to doing our dosing work to do the bridging and then also some optimization. Then you should hear more from us after we've engaged with FDA and what our global clinical plan looks like. But the goal here is to move quickly into late-stage studies in PMN, FSGS, and MCD. I'll round things out by just ending on the financial foundation that is continuing to strengthen for Travere. Most recently, we had, at the end of last quarter, $472 million in cash and equivalents, and we had growing revenues up to $220 million, nearly 100% growth year-over-year.

An extremely strong foundation, a clear sightline to profitability, and the ability to continue investing in all the priorities that we've talked about and the programs that we've talked about here today. We're on a great trajectory to be able to achieve the $3 billion in net product sales for FILSPARI by 2033 and continue layering in these additional growth opportunities to the pipeline. With that, I will wrap things up and say thank you for listening to Travere, and that's it. Thank you, guys.